Cultivating regenerative medicine innovation in China.

@article{McMahon2010CultivatingRM,
  title={Cultivating regenerative medicine innovation in China.},
  author={Dominique S. McMahon and Halla Thorsteinsd{\'o}ttir and Peter A. Singer and Abdallah S. Daar},
  journal={Regenerative medicine},
  year={2010},
  volume={5 1},
  pages={
          35-44
        }
}
AIM While China has become a significant contributor and prolific publisher in regenerative medicine, its role in the field is not well understood. We analyze how capacity in regenerative medicine was built in China to identify some of its main strengths and challenges. MATERIALS & METHODS This case study of regenerative medicine in China is primarily based on interviews with experts in China, including researchers, policy makers, clinicians, representatives of firms and regulators. RESULTS… 

Figures and Tables from this paper

China's landscape in regenerative medicine.

Regenerative Medicine in China: The Capacity, Capability and Reliability

China needs to develop standards, regulations and management practices suitable for the healthy development of RM, and aspects that should be strengthened include sound administrative systems, laws, and technical specifications and guidelines.

Regenerative medicine in China: main progress in different fields

Aspects that should be strengthened include sound administrative systems, laws, and technical specifications and guidelines; conservation of stem cell resources; emphasis on training and retention of talented stem cell researchers; and reasonable allocation of resources, diversification of investment and breakthroughs in key areas.

All the eggs in one basket: a look at regenerative medicine clusters in Brazil and China and India

Regenerative medicine (RM) is a science intensive biomedical field that remains out of the grasp of most developing countries, yet the governments of China India and Brazil have prioritized its

Regenerative medicine in Brazil: small but innovative.

Although Brazil's contribution to the RM sector is small, its niche emphasis on clinical applications may become of global importance, particularly if Brazil manages to address the challenges currently impinging on RM innovation.

Regenerative Medicine in South Korea: Bridging the Gap Between Authorization and Reimbursement

A wide gap between manufacturers, regulatory bodies, and health technology bodies regarding reimbursements for RMs focused cell therapy products is examined and an alternative framework of value-based pricing is demanded.

Innovative drugs and vaccines in China, India and Brazil

This work focuses more directly on innovative vaccines and therapeutics in the pipelines of indigenous enterprises in China, India and Brazil, and examines the impact of in vivo toxicity studies, the overall nature and frequency of the toxicities observed, and the patient population and/or disease indication being considered.

Sino-Canadian Collaborations in Stem Cell Research: A Scientometric Analysis

A scientometric analysis of the China–Canada collaboration in stem cell research establishes an objective baseline for comparison with future studies, setting the stage for in-depth exploration of the dynamics and genesis of IC in stemcell research.

Lost in translation? Accountability and governance of clinical stem cell research in China.

  • J. Zhang
  • Political Science
    Regenerative medicine
  • 2017
By examining China's regulatory trajectory in the last 15 years, this paper illustrates that it is a post hoc pragmatic policy rationale and a soft centralization regulatory approach that have hampered China's governance.

References

SHOWING 1-10 OF 24 REFERENCES

China and the global stem cell bioeconomy: an emerging political strategy?

The UK's recent political strategy on stem cell science is introduced and an in-depth discussion of the formal organization of China's research and development in the area is developed, as well as its rapidly evolving commercial, regulatory and ethical environment.

Stem cell research in China

China has the most liberal and favourable environments for human embryonic stem cell research and clinical applications of stem cells in the treatment of acute heart failure, acute liver failure and lower limb ischaemia have been reported by many hospitals.

Cellular Transplants in China: Observational Study from the Largest Human Experiment in Chronic Spinal Cord Injury

Perioperative morbidity and lack of functional benefit were identified as the most serious clinical shortcomings and physicians should not recommend this procedure to patients.

An overview of stem cell-based clinical trials in China.

This review focuses on therapeutic applications of ASCs derived from bone marrow and peripheral blood and discusses concerns related to regulations monitoring stem cell-based clinical trials.

Ethics: China already has clear stem-cell guidelines

Cloning publications should include clear information about the steps taken to ensure that egg donors gave their informed and voluntary consent to donation, and researchers using human eggs should be independent of any fertility clinics treating the women from whom the eggs came.

Stem-cell therapy faces more scrutiny in China

Stem-cell scientists in China contacted by Nature hope that the new regulations came into effect on 1 May may help to curtail a growing trade in unproven treatments that attract patients from around the world, risking their health and potentially damaging the reputation of stem-cell research.

Potential of olfactory ensheathing cells for cell-based therapy in spinal cord injury.

A number of controversial issues related to OEC biology and transplantation must be addressed to understand the rationale and expectations for OEC cell therapy approaches in SCI, and information is provided on these issues for spinal cord medicine clinicians.

China's struggle for practical regulations in medical ethics

Despite its introduction, there are concerns about whether China is prepared to embrace the standards it claims to have adopted, and Chinese bioethicists find themselves torn between the necessity to create a fully-fledged modern health-care system and aspirations to become global players in the biomedical sciences.

Profile: Hui Zhen Sheng

As a stem cell scientist in China, Hui Zhen Sheng has had more trouble in the past few years than most researchers have encountered. But you'll never hear her complain about it.